Promakhos Therapeutics was founded with the mission to harness bacterial molecules to activate the body's innate ability to manage inflammation and promote healing. The company's vision is to create a platform capable of addressing a range of inflammatory disorders. Their initial focus is on developing treatments for Crohn’s Disease, which impacts over 500,000 Americans and incurs an annual cost of $10 billion. Following this, Promakhos aims to extend its therapeutic solutions to type 1 Diabetes and Multiple Sclerosis.
Promakhos Therapeutics has attracted notable investors and experts in the biotechnology field, contributing to its rapid development and innovative approach. The company has achieved significant milestones in preclinical trials, demonstrating the potential efficacy of its bacterial molecule-based therapies. By targeting chronic inflammatory diseases with high unmet medical needs, Promakhos is poised to make a substantial impact on patient outcomes and healthcare costs.
